Phatisa’s Food Fund 2 has finalized the sale of its stake in Deltamune, a South African-based vaccine manufacturer specializing in animal health, to Vaxxinova International, a global player in the animal health sector and a subsidiary of the Germany-based EW Group. While the financial terms of the transaction remain undisclosed, the deal marks a significant milestone in the evolution of Africa’s veterinary vaccine industry.
Founded in 1995, Deltamune has built a strong reputation for developing and manufacturing vaccines for production animals, with a primary focus on poultry and a growing footprint in the ruminant segment, including cattle and sheep. The company currently produces nearly 15 million vaccine doses annually, serving customers across 12 countries in the SADC and COMESA regions.
Phatisa, in partnership with Deltamune’s management team, acquired 100% ownership of the company from HL Hall & Sons in 2022. The acquisition, structured as a management buyout, was accompanied by a capital injection that enabled Deltamune to expand its product portfolio, scale operations, and enter new regional markets.
“Our partnership with Deltamune embodies Phatisa’s commitment to backing innovation that delivers regional value and global relevance,” said Imane El Alaoui, Partner at Phatisa. “This exit is more than a strong outcome—it is proof that local production capabilities, when scaled responsibly, can help Africa lead on food security, vaccine access, and pandemic resilience. We are proud to have accompanied Deltamune on this journey and wish the team and Vaxxinova continued success.”
Dr. Stefan Swanepoel, Managing Director of Deltamune, emphasized the transformative impact of Phatisa’s involvement:
Phatisa’s support enabled Deltamune to scale our reach, expand our product offering, and deepen our role in strengthening animal health across the region. With Vaxxinova, we will build on that foundation—advancing Africa’s ability to respond quickly and locally to both endemic and emerging animal health threats.
Victor van Solinge, CEO of Vaxxinova, welcomed the acquisition as a strategic fit:
We are excited to welcome Deltamune to the Vaxxinova group. This is a perfect cultural, strategic, and operational fit where all stakeholders in and outside South Africa will benefit. In sub-Saharan Africa, the combined companies will offer an enriched portfolio of products and services. The now extended Vaxxinova group and its customers will benefit from the exchange of technologies and expertise. We are grateful to Phatisa for allowing us to acquire Deltamune.
This acquisition strengthens Vaxxinova’s presence in sub-Saharan Africa and enhances its ability to deliver localized, science-driven solutions to the region’s growing animal health needs. For Deltamune, the partnership opens new pathways for innovation, market expansion, and global collaboration.
